Exchange: NasdaqCM Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
1.40% $2.18
America/New_York / 28 sep 2023 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 52.76 mill |
EPS: | 0 |
P/E: | 0 |
Earnings Date: | Oct 10, 2023 |
SharesOutstanding: | 24.20 mill |
Avg Daily Volume: | 0.227 mill |
RATING 2023-09-25 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Neutral | |
DE: | Strong Sell | |
P/E: | Strong Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 0 | sector: PE 0 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.04x |
Company: PE 0 | industry: PE 47.78 |
DISCOUNTED CASH FLOW VALUE |
---|
$2.43 (11.49%) $0.250 |
Date: 2023-09-28 |
Expected Trading Range (DAY) |
---|
$ 1.912 - 2.45 ( +/- 12.29%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.18 (1.40% ) |
Volume | 0.0501 mill |
Avg. Vol. | 0.227 mill |
% of Avg. Vol | 22.05 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.